全文获取类型
收费全文 | 213964篇 |
免费 | 17990篇 |
国内免费 | 7287篇 |
专业分类
耳鼻咽喉 | 1663篇 |
儿科学 | 2744篇 |
妇产科学 | 2612篇 |
基础医学 | 31795篇 |
口腔科学 | 3473篇 |
临床医学 | 16461篇 |
内科学 | 40148篇 |
皮肤病学 | 2788篇 |
神经病学 | 15034篇 |
特种医学 | 4516篇 |
外国民族医学 | 52篇 |
外科学 | 14592篇 |
综合类 | 29772篇 |
现状与发展 | 19篇 |
一般理论 | 7篇 |
预防医学 | 10910篇 |
眼科学 | 2193篇 |
药学 | 33690篇 |
62篇 | |
中国医学 | 9224篇 |
肿瘤学 | 17486篇 |
出版年
2024年 | 176篇 |
2023年 | 3751篇 |
2022年 | 5198篇 |
2021年 | 9866篇 |
2020年 | 8334篇 |
2019年 | 7056篇 |
2018年 | 6860篇 |
2017年 | 6723篇 |
2016年 | 6941篇 |
2015年 | 8120篇 |
2014年 | 13343篇 |
2013年 | 14439篇 |
2012年 | 12879篇 |
2011年 | 14916篇 |
2010年 | 12115篇 |
2009年 | 12400篇 |
2008年 | 12031篇 |
2007年 | 11053篇 |
2006年 | 9820篇 |
2005年 | 8514篇 |
2004年 | 7100篇 |
2003年 | 6297篇 |
2002年 | 4964篇 |
2001年 | 4078篇 |
2000年 | 3436篇 |
1999年 | 2975篇 |
1998年 | 2435篇 |
1997年 | 2350篇 |
1996年 | 2069篇 |
1995年 | 2127篇 |
1994年 | 1924篇 |
1993年 | 1673篇 |
1992年 | 1439篇 |
1991年 | 1328篇 |
1990年 | 1104篇 |
1989年 | 963篇 |
1988年 | 913篇 |
1987年 | 761篇 |
1986年 | 689篇 |
1985年 | 1073篇 |
1984年 | 978篇 |
1983年 | 672篇 |
1982年 | 705篇 |
1981年 | 556篇 |
1980年 | 472篇 |
1979年 | 383篇 |
1978年 | 272篇 |
1977年 | 221篇 |
1976年 | 205篇 |
1975年 | 141篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
11.
《The Journal for Nurse Practitioners》2022,18(2):245-247
Transient stress hyperglycemia in the setting of acute myocardial infarction is a frequent phenomenon. Its transient nature should not dissuade the clinician from management of elevated blood glucose in a patient after an ST-elevation myocardial infarction. This case presents an adult patient after an ST-elevation myocardial infarction with transient stress hyperglycemia and the evidence used to identify optimal pharmacologic management and secondary prevention. 相似文献
12.
13.
《The Journal for Nurse Practitioners》2022,18(4):370-371
From the early days of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there were concerns that nebulizers used for the treatment of respiratory diseases as aerosol-generating devices could enhance the transmission of SARS-CoV-2. However, given the absence of any compelling data showing that nebulized treatments increase the risk of SARS-CoV-2 infection, it is unnecessary for community-dwelling patients with respiratory diseases to alter their current therapies, including nebulized treatments, to prevent symptom exacerbations. Maintaining current inhaled therapies also minimizes the risk of hospitalization and hospital-acquired infection of SARS-CoV-2. 相似文献
14.
15.
16.
17.
《Clinical microbiology and infection》2022,28(8):1152.e1-1152.e6
ObjectivesDespite the possibility of concurrent infection with COVID-19 and malaria, little is known about the clinical course of coinfected patients. We analysed the clinical outcomes of patients with concurrent COVID-19 and malaria infection.MethodsWe conducted a retrospective cohort study that assessed prospectively collected data of all patients who were admitted between May and December 2020 to the Universal COVID-19 treatment center (UCTC), Khartoum, Sudan. UCTC compiled demographic, clinical, laboratory (including testing for malaria), and outcome data in all patients with confirmed COVID-19 hospitalized at that clinic. The primary outcome was all-cause mortality during the hospital stay. We built proportional hazard Cox models with malaria status as the main exposure and stepwise adjustment for age, sex, cardiovascular comorbidities, diabetes, and hypertension.ResultsWe included 591 patients with confirmed COVID-19 diagnosis who were also tested for malaria. Mean (SD) age was 58 (16.2) years, 446/591 (75.5%) were males. Malaria was diagnosed in 270/591 (45.7%) patients. Most malaria patients were infected by Plasmodium falciparum (140/270; 51.9%), while 121/270 (44.8%) were coinfected with Plasmodium falciparum and Plasmodium vivax. Median follow-up was 29 days. Crude mortality rates were 10.71 and 5.87 per 1000 person-days for patients with and without concurrent malaria, respectively. In the fully adjusted Cox model, patients with concurrent malaria and COVID-19 had a greater mortality risk (hazard ratio 1.43, 95% confidence interval 1.21-1.69).DiscussionCoinfection with COVID-19 and malaria is associated with increased all-cause in-hospital mortality compared to monoinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 相似文献
18.
Andreas Lundin Martin Annborn Ola Borgquist Joachim Düring Johan Undén Christian Rylander 《Acta anaesthesiologica Scandinavica》2023,67(5):655-662
Patients admitted to intensive care after cardiac arrest are at risk of circulatory shock and early mortality due to cardiovascular failure. The aim of this study was to evaluate the ability of the veno-arterial pCO2 difference (∆pCO2; central venous CO2 – arterial CO2) and lactate to predict early mortality in postcardiac arrest patients. This was a pre-planned prospective observational sub-study of the target temperature management 2 trial. The sub-study patients were included at five Swedish sites. Repeated measurements of ∆pCO2 and lactate were conducted at 4, 8, 12, 16, 24, 48, and 72 h after randomization. We assessed the association between each marker and 96-h mortality and their prognostic value for 96-h mortality. One hundred sixty-three patients were included in the analysis. Mortality at 96 h was 17%. During the initial 24 h, there was no difference in ∆pCO2 levels between 96-h survivors and non-survivors. ∆pCO2 measured at 4 h was associated with an increased risk of death within 96 h (adjusted odds ratio: 1.15; 95% confidence interval [CI]: 1.02–1.29; p = .018). Lactate levels were associated with poor outcome over multiple measurements. The area under the receiving operating curve to predict death within 96 h was 0.59 (95% CI: 0.48–0.74) and 0.82 (95% CI: 0.72–0.92) for ∆pCO2 and lactate, respectively. Our results do not support the use of ∆pCO2 to identify patients with early mortality in the postresuscitation phase. In contrast, non-survivors demonstrated higher lactate levels in the initial phase and lactate identified patients with early mortality with moderate accuracy. 相似文献
19.
20.
目的 评价美国国家电器制造协会(National Electrical Manufactures Association, NEMA)最新标准(NU 2-2018)在正电子发射型计算机断层显像/电子计算机断层显像(positron emission tomography/computed tomography, PET/CT)设备性能检测中的作用。 方法 依据最新的NEMA NU 2-2018标准,检测西门子Biograph Vision PET/CT的空间分辨率、灵敏度、散射分数、计数丢失、随机符合、飞行时间分辨率、计数丢失率和随机符合校正精度、图像质量、衰减和散射校正精度及PET与CT配准精度指标。 结果 距视野中心1 cm处横向和轴向空间分辨率分别为3.75 mm和3.76 mm;在视野中心和轴向10 cm处的灵敏度分别为16.83 kcps/MBq和16.67 kcps/MBq;放射性浓度为27.37 kBq/mL时,最大等效噪声计数率为258.26 kcps,散射分数为38.58%;系统时间分辨率为209.82 ps;图像质量模型的对比度恢复系数范围为88.9%~96.2%,背景变异系数范围为2.05%~6.80%,平均肺插件残余误差为2.43%;计数丢失和随机符合校正最大误差为3.9%;距离床板末端 5 cm 和 100 cm处,在距视野中心Y轴1 cm处,PET和CT的配准精度分别为0.46 mm和1.07 mm,在距视野中心X轴20 cm处,PET和CT的配准精度分别为1.06 mm和1.45 mm,在距视野中心Y轴20 cm处PET和CT的配准精度分别为0.85 mm和1.15 mm。 结论 NEMA NU 2-2018标准检测条件更加接近临床,能更好地反映PET/CT设备的系统性能。 相似文献